Should *CYP2C19* Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?

This article was published in the following Dove Press journal:
Pharmacogenomics and Personalized Medicine

Jialin Sun^{1,*}
Ping Leng¹
Chen Sun²
Wen Xu¹
Zhenhuan Zhao¹
Xiao Li¹
Xiaolei Zhang¹
Jing Li^{1,*}

¹Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, People's Republic of China; ²Department of Pharmacy, Qingdao Municipal Hospital, Qingdao 266003, Shandong, People's Republic of China

*These authors contributed equally to this work

Background: There have been few studies on *CYP2C19* genotypes and clopidogrel response associated with ischemic stroke (IS), especially IS complicated by type 2 diabetes mellitus (T2DM). This study aimed to investigate the possible association between *CYP2C19* polymorphisms and high on-treatment platelet reactivity (HTPR) in IS patients with T2DM in China.

Patients and Methods: A total of 426 consecutive IS patients with T2DM were enrolled in this case-control study and they were divided into HTPR group and non-HTPR group according to the ADP-induced platelet inhibition (PIADP) assessed by thromboelastography (TEG). Genotypes were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Various clinical and demographic data were also recorded. The association between *CYP2C19* genetic variants and platelet function was assessed.

Results: Carriers of *CYP2C19**2 heterozygous and mutant homozygous genotypes showed significantly lower PIADP than non-carriers (27.2% vs 38.3%, $p < 0.001$; 27.41% vs 38.3%, $p = 0.012$, respectively). Compared with the control group, the *CYP2C19**2 A allele was more frequent in the HTPR group (34.51% vs 25.82%, $p = 0.002$). The carriage of *CYP2C19**2 mutant allele was significantly associated with increased risk of HTPR (odds ratio (OR) = 1.94, 95% confidence interval (CI) = 1.32–2.85). There was no significant correlation between *CYP2C19**3 or *17 genotypes and HTPR risk.

Conclusion: *CYP2C19**2 mutant allele was associated with attenuated platelet response to clopidogrel and increased risk of HTPR in IS patients with T2DM, suggesting that *CYP2C19**2 polymorphism might be an important predictor of HTPR in this high-risk population.

Keywords: clopidogrel, ischemic stroke, type 2 diabetes mellitus, *CYP2C19*, high on-treatment platelet reactivity

Correspondence: Jialin Sun; Jing Li
Department of Pharmacy, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Shinan District, Qingdao 266003, Shandong, People's Republic of China
Tel +86-532-82912261;
+86-532-82911566
Email sjlsyyk-412@163.com;
stella_71@tom.com

Introduction

Stroke is a globally fatal disease that can be classified into two categories: ischemic and hemorrhagic. Among them, ischemic stroke (IS) is the main type, accounting for 70% to 80% of stroke patients. It is characterized by high morbidity, mortality, and disability, as well as high relapse rate. According to the guidelines for the early management of patients with acute ischemic stroke, antiplatelet therapy is considered

an important treatment for secondary prevention of IS.^{1,2} Clinical studies have shown that long-term antiplatelet therapy can reduce the incidence of vascular events (for example, myocardial infarction, stroke, and vascular death) by 15%–34%.³ The antiplatelet drug clopidogrel is recommended as an effective treatment according to current guidelines.^{1,2}

Although many studies have confirmed the clinical efficacy of clopidogrel as an antithrombotic agent, its effectiveness in preventing platelet aggregation is not consistent in all patients.^{4–6} 5–44% of patients receiving this drug show high platelet reactivity, leading to a number of subsequent ischemic events.⁷ Such a situation is called high on-treatment platelet reactivity (HTPR). Many studies have indicated that patients with HTPR are more likely to have adverse ischemic events,^{8–11} with diabetes mellitus (DM) patients being at a higher risk, about two- to fourfolds increased risk compared with non-DM patients, and being considered to be a high-risk group.^{11–13} The mechanisms leading to HTPR in DM patients have not been fully elucidated, and a variety of factors have been identified, including genetic, demographic, and clinical factors.^{14–16}

As a prodrug, clopidogrel requires metabolic activation through the hepatic cytochrome P450 (CYP450) system. *CYP2C19* is the main metabolic enzyme of the CYP450 system and plays an important role in the oxidative activation of clopidogrel.¹⁷ Its polymorphisms are thought to be closely related to the poor clopidogrel response. *CYP2C19**2 (681G > A, rs4244285) and *CYP2C19**3 (636G > A, rs4986893) are the most common loss-of-function (LOF) alleles in the Asian population (frequency of 25–35% and 5–15%, respectively), while *CYP2C19**17 (–806C > T, rs12248560) is a gain-of-function (GOF) allele.¹⁸ In China, approximately 35% of the population are carriers of *CYP2C19* LOF alleles, higher than that of Caucasians and Africans (15%).^{18,19} Studies have shown that there is a correlation between *CYP2C19* LOF genotypes and HTPR in IS patients.^{20–22} However, there is no information about the impact of *CYP2C19* alleles on IS patient with type 2 diabetes mellitus (T2DM), who is a special group with particular metabolic profiles.

Therefore, this study aimed to investigate the possible association between *CYP2C19* polymorphisms and HTPR in Chinese Han patients with IS complicated by T2DM. The data obtained may help to improve individualized antiplatelet therapy opinions and reduce adverse side effects in IS patients with T2DM.

Patients and Methods

Study Protocol

We conducted a case-control study consisting of consecutive patients with IS complicated by T2DM from the Chinese Han population who were admitted to the Affiliated Hospital of Qingdao University between January 2018 and October 2019. The inclusion criteria were as follows: diagnosis of IS with computer tomography or magnetic resonance imaging; diagnosis of T2DM according to the International Diabetes Federation criteria;²³ older than 18 years; continuous clopidogrel treatment for 7 to 10 days, with platelet function testing. Exclusion criteria included: exposure to thienopyridine or glycoprotein IIb/IIIa inhibitor within 1 week; diagnosis of severe kidney or liver diseases; inability to give informed consent. Furthermore, to determine whether the results of this study were specific to patients with T2DM, pharmacodynamics evaluations were also extended to a cohort of IS patients without T2DM. We included the same sample size for each group. The study was conducted in accordance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University. Written informed consent was obtained from each participant.

Clinical Data Collection

The demographic characteristics and baseline data were collected and evaluated, including general condition (age, gender, and body mass index (BMI)), personal history (smoking and drinking), medical history (hypertension, dyslipidemia, coronary artery disease, peripheral arterial disease, previous percutaneous coronary intervention (PCI) and previous stroke), laboratory tests, and use of other medications (insulin, oral hypoglycemic agents, aspirin, lipid-lowering drugs, β -blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and proton-pump inhibitors (PPIs)). These data were obtained through reviewing medical records of the hospital.

ADP-Induced Platelet Aggregation Test

ADP-induced platelet inhibition (PIADP) was measured by TEG[®] 5000 Thrombelastograph[®] Hemostasis Analyzer system (Haemoscope Co., Niles, IL, USA). Venous blood was drawn from patients on an empty stomach in the morning within 7 to 10 days of clopidogrel treatment.

The first 2 to 4 mL of blood was discarded to avoid spontaneous platelet activation. 2.7 mL of venous blood anticoagulated with 3.2% sodium citrate and 4.0 mL of venous blood anticoagulated with 14.7 U mL⁻¹ lithium heparin were extracted and tested within 2 hrs.

The analyzer had three channels: 20 µL of 0.2 mol L⁻¹ CaCl₂ and 340 µL of blood anticoagulated with sodium citrate and mixed with Kaolin were added to channel 1; 10 µL of activator F and 360 µL of heparin-anticoagulated blood were added to channel 2; and 10 µL of activator F, 10 µL of ADP, and 360 µL of heparin-anticoagulated blood were added to channel 3. PIADP was calculated by the instrument software and the results were expressed as a percentage (%). Patients with PIADP < 30% belonged to the HTPR group (case group).

CYP2C19 Genotyping

Three single nucleotide polymorphisms (SNPs) of *CYP2C19*, including *CYP2C19**2, *3, and *17, were genotyped in this study by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method. Genomic DNA was extracted from citrated whole blood with commercially available kits (DP348 Blood Genomic DNA Extraction Kit, Tianjian Biotechnology Co., Ltd., Beijing, China) according to the manufacturer's instructions. Genotyping was performed on a 7500 real-time PCR System (Applied Biosystems, Foster City, CA, USA) using the *CYP2C19* Genotyping Assay Kit (Shandong Biomultitech Co., Ltd., Shandong, China) following the supplier's protocols. The results were analyzed by Applied Biosystems 7500 Real-Time PCR System Sequence Detection Software v1.4.1. Control DNAs supplied by the manufacturer were genotyped to ensure accuracy.

Sample Size Calculation

The sample size was calculated using PASS Software v15.0 (NCSS, LLC, Kaysville, UT, USA). It was estimated that at least 56 HTPR participants would be required to detect an odds ratio (OR) of 2.654 with an expected prevalence of *CYP2C19**2 allele of 0.288,^{24,25} a power of 90% and a two-sided alpha-level of 0.05. To ensure accuracy, we included a larger and equal sample size for each group.

Statistical Analysis

Data were analyzed by IBM SPSS Statistics Software v26.0 (IBM Co., Armonk, NY, USA). Continuous variables were presented as mean and standard deviation (SD) or median

and quartile ranges (for non-normally distributed data). Categorical variables were expressed as numbers or percentages. The normality of continuous variables was evaluated using the Shapiro–Wilk test, with homogeneity verified by the Levene test. Continuous variables between groups were compared by the Student's *t*-test or the Mann–Whitney *U*-test, as appropriate. Categorical variables were compared using the χ^2 test (or Fisher exact test for expected counts less than 5). The χ^2 test was also used to evaluate differences in allele and genotype frequencies between groups, and to determine whether individual polymorphism was in Hardy–Weinberg equilibrium (HWE). Result with a two-tailed *p* value < 0.05 was considered statistically significant.

Results

Baseline Characteristics and Platelet Reactivity

We consecutively recruited 426 IS patients with T2DM who were all from the Chinese Han population. The median PIADP of the entire subject, the case group, and the control group was 30.05% (IQR, 21.1–58.6%), 21.1% (IQR, 12.95–25.8%), and 58.6% (IQR, 44.20–75.05%), respectively. Table 1 lists the baseline demographics, clinical characteristics, and laboratory data of the study population. No significant differences in the baseline characteristics between the HTPR and non-HTPR groups were observed.

The baseline characteristics of the IS study population without T2DM are shown in Table S1. The differences between the HTPR and non-HTPR groups were not statistically significant (*p* > 0.05).

Genotyping results

Table 2 shows the genotyping results of *CYP2C19* in the IS patients with T2DM. The genetic distribution of the assessed polymorphisms did not deviate from the HWE (*p* > 0.05). The frequencies of *CYP2C19**2, *3, and *17 mutant allele carriers in this population were 50.94%, 12.21%, and 4.46%, respectively. Results showed that the Chinese had a high prevalence of *CYP2C19**2 A allele (30.16%), but a relatively low prevalence of *3 A (6.46%) and *17 T (2.35%) alleles. Similar results could be observed in the cohort of IS patients without T2DM (Table S2). The genetic distribution of the evaluated polymorphisms was consistent with previously reported findings.^{18,26}

The distribution of *CYP2C19**2, *3, and *17 genotypes of the study population is presented in Table 3. Compared

Table 1 Baseline Characteristics of the Study Population

Variables [#]	Overall	HTPR	Non-HTPR	p value [*]
	(n = 426)	(n = 213)	(n = 213)	
Age, years	69 (62–74)	69 (63–74.5)	69 (61–73)	0.359
Male, n (%)	294 (69.01)	139 (65.26)	155 (72.77)	0.094
BMI, kg/m ²	25.67 (23.88–27.68)	25.53 (23.88–28.09)	25.81 (24.22–27.51)	0.772
Active smoking, n (%)	161 (37.79)	74 (34.74)	87 (40.85)	0.250
Drinking, n (%)	121 (28.40)	54 (25.35)	67 (31.46)	0.171
Hypertension, n (%)	99 (23.24)	47 (22.07)	52 (24.41)	0.566
Dyslipidemia, n (%)	27 (6.34)	12 (5.63)	15 (7.04)	0.551
Coronary artery disease, n (%)	143 (33.57)	72 (33.80)	71 (33.33)	0.918
Peripheral arterial disease, n (%)	48 (11.27)	21 (9.86)	27 (12.68)	0.358
Previous PCI, n (%)	39 (9.15)	19 (8.92)	20 (9.39)	0.867
Previous stroke, n (%)	58 (13.62)	24 (11.27)	34 (15.96)	0.158
Platelet count, ×10 ⁹ /L	203.5 (173.25–238)	202.5 (173–229.75)	204 (175–246.75)	0.542
Leucocytes, ×10 ⁹ /L	6.79 (5.8–8.07)	6.78 (5.84–7.92)	6.8 (5.71–8.26)	0.903
Hemoglobin, g/L	133.23 ± 16.05	133.08 ± 16.95	133.38 ± 15.12	0.928
Fasting blood glucose, mmol/L	6.92 (5.56–8.52)	6.89 (5.56–8.62)	6.93 (5.55–8.41)	0.644
HbA1c, %	7.6 (6.7–9)	7.7 (7–9.3)	7.53 (6.5–8.3)	0.848
TC, mmol/L	3.96 (3.15–4.95)	4.01 (3.22–5)	3.9 (3.11–4.84)	0.421
LDL-C, mmol/L	2.16 (1.61–2.89)	2.29 (1.65–2.92)	2.03 (1.58–2.87)	0.085
HDL-C, mmol/L	1.07 (0.94–1.22)	1.07 (0.95–1.24)	1.07 (0.94–1.22)	0.693
TG, mmol/L	1.39 (0.95–2.08)	1.4 (0.94–2.08)	1.35 (0.97–2.09)	0.999
BUN, mmol/L	5.42 (4.41–6.74)	5.41 (4.53–7)	5.46 (4.25–6.52)	0.334
Cr, μmol/L	83.4 (66–96.88)	81.7 (63–97)	84.5 (70.15–96.5)	0.174
UA, μmol/L	309 (252.75–371)	311 (256.5–373.7)	300.9 (249.25–359)	0.270
HCY, μmol/L	11.88 (9.4–14.25)	13.1 (11.63–14.7)	10.1 (9.35–14.31)	0.301
CRP, mg/L	2.14 (1.29–4.38)	1.96 (1.28–3.46)	2.42 (1.27–5.96)	0.463
Insulin, n (%)	113 (26.53)	52 (24.41)	61 (28.64)	0.323
Oral hypoglycemic agent, n (%)	197 (46.24)	101 (47.42)	96 (45.07)	0.627
Aspirin, n (%)	179 (42.02)	84 (39.44)	95 (44.60)	0.280
Statin, n (%)	183 (42.96)	85 (39.91)	98 (46.01)	0.203
β-blocker, n (%)	153 (35.92)	75 (35.21)	78 (36.62)	0.762
ACEI, n (%)	77 (18.08)	32 (15.02)	45 (21.13)	0.102
ARB, n (%)	115 (27.00)	52 (24.41)	63 (29.58)	0.230
CCB, n (%)	140 (32.86)	70 (32.86)	70 (32.86)	1.000
PPI, n (%)	161 (37.79)	86 (40.38)	75 (35.21)	0.272

Notes: [#]Quantitative data are expressed as mean ± standard deviation or median (1st–3rd quartiles). ^{*}Variable is significantly different between HTPR and non-HTPR groups at p value < 0.05. Qualitative data are presented as numbers (%).

Abbreviations: BMI, body mass index; PCI, percutaneous coronary intervention; HbA1c, Hemoglobin A1c; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; BUN, blood urea nitrogen; Cr, creatinine; UA, uric acid; HCY, homocysteine; CRP, C-reactive protein; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; PPI, proton-pump inhibitor.

with the non-HTPR group, the frequency of the *CYP2C19**2 A allele was significantly higher in the HTPR group (34.51% vs 25.82%, $p = 0.002$). And the odds of HTPR among patients with a *CYP2C19**2 A allele is 1.94 times the odds of HTPR among those without this mutant allele (Figure 1). There were no significant differences in allele frequencies of the remaining two SNPs between the two groups.

Table S3 represents the distribution of *CYP2C19* genotypes of the cohort of IS patients without T2DM. No

significant differences in genotype and allele frequencies were observed ($p > 0.05$).

*CYP2C19**2 Genotypes and Platelet Activity

In this study, individuals carrying the *CYP2C19**2 A allele had a lower PIADP than non-carriers (27.3% (IQR, 17.1–50.3%) vs 38.3% (IQR, 23.8–66.5%), $p < 0.001$). In addition, the PIADP was similar in GA and AA genotypes ($p = 0.897$),

Table 2 Distribution of *CYP2C19**2, *3, and *17 Genotypes in the Patients

Gene	SNP ID	Genotype/Allele	Number	Frequency (%)	HWE <i>p</i> value*
<i>CYP2C19</i> *2	rs4244285	GG	209	49.06	0.776
		GA	177	41.55	
		AA	40	9.39	
		Any A allele	257	30.16	
<i>CYP2C19</i> *3	rs4986893	GG	374	87.79	0.326
		GA	49	11.50	
		AA	3	0.70	
		Any A allele	55	6.46	
<i>CYP2C19</i> *17	rs12248560	CC	407	95.54	0.106
		CT	18	4.23	
		TT	1	0.23	
		Any T allele	20	2.35	

Note: *The genetic polymorphism distribution is considered to deviate from HWE at *p* value < 0.05.

Table 3 Distribution of *CYP2C19**2, *3, and *17 Genotypes in Clopidogrel Responders and Non-Responders

Gene	SNP ID	Genotype/Allele	HTPR	Non- HTPR	<i>p</i> value*
			(n = 213)	(n = 213)	
<i>CYP2C19</i> *2	rs4244285	GG, n (%)	87 (40.85)	122 (57.28)	0.002*
		GA, n (%)	105 (49.3)	72 (33.8)	
		AA, n (%)	21 (9.86)	19 (8.92)	
<i>CYP2C19</i> *3	rs4986893	GG, n (%)	186 (87.32)	188 (88.26)	0.616
		GA, n (%)	25 (11.74)	24 (11.27)	
		AA, n (%)	2 (0.94)	1 (0.47)	
<i>CYP2C19</i> *17	rs12248560	CC, n (%)	206 (96.71)	201 (94.37)	0.348
		CT, n (%)	7 (3.29)	11 (5.16)	
		TT, n (%)	0 (0)	1 (0.47)	

Note: *Variable is significantly different between HTPR and non-HTPR groups at *p* value < 0.05.

but differed between GG and each of the other two genotypes (GA, *p* < 0.001; AA, *p* = 0.012; Figure 2A).

The PIADP of the three *CYP2C19**2 genotypes in the case and control groups was also compared, and the results are shown in Figure 2B and C, respectively. Compared with wild-type patients, the *CYP2C19**2 mutant allele carriers of both groups had lower PIADP, but the difference was only significant in the HTPR group (*p* = 0.024). Comparison between different genotypes showed that the PIADP difference between *CYP2C19**2 GG and AA genotypes in the HTPR group was significant (*p* = 0.016), while there was no significant difference between other genotypes (*p* > 0.05).

Discussion

Many studies have shown that compared with non-T2DM patients, T2DM patients have a higher incidence of HTPR,

which will lead to a higher risk of adverse vascular events.^{11,12,14–16} Therefore, it is of great significance to take strategies to predict and identify patients with HTPR, as they may benefit from other antiplatelet drugs to prevent ischemic events and improve clinical outcomes.

Although, some convincing genetic studies have demonstrated that *CYP2C19**2 mutant allele is associated with diminished metabolic activation of clopidogrel, decreased drug responsiveness, and increased risk of adverse vascular events in clopidogrel-treated patients, the clinical application of *CYP2C19* genotyping remains controversial.^{22,27–29} Importantly, these early studies focused on patients with coronary heart disease rather than stroke, especially those with IS and T2DM. To the best of our knowledge, this was the first study to investigate patients with IS complicated by T2DM. We aimed to

Figure 1 Association between *CYP2C19* genotypes and the risk of HTPR in IS patients with or without T2DM. Carriers were defined as patients with at least one mutant allele.

Figure 2 Box plots of ADP-induced platelet inhibition for each *CYP2C19**2 genotype in the entire subject (**A**, n = 426), HTPR group (**B**, n = 213), and non-HTPR group (**C**, n = 213).

clarify the association between *CYP2C19* gene polymorphisms and the antiplatelet efficacy of clopidogrel in this population.

In the present study, we observed that the frequencies of *CYP2C19**2 and *3 mutant alleles in the Chinese Han

population were consistent with those reported by Yan et al (30.38% and 7.08%) and were higher than those reported in Swedish Caucasians and Ethiopians.^{18,26} The frequency of *CYP2C19**17 T allele in our cohort was lower than that in other races, confirming that allelic

variants exhibit ethnic and geographic diversity.¹⁸ The genetic distribution of *CYP2C19* polymorphisms was similar in T2DM and non-T2DM patients, indicating that there might be no direct correlation between *CYP2C19* genetic variants and the occurrence of T2DM. This was also confirmed by Semiz et al.³⁰

Correlation analysis showed that the carriage of *CYP2C19**2 mutant allele was a related factor for HTPR in T2DM patients, similar to the results of previous studies, but was not statistically significant in non-T2DM patients.^{31,32} Therefore, routine *CYP2C19**2 genotyping could be recommended as a straightforward approach for optimizing clopidogrel utilization in patients with IS, especially those complicated by T2DM. Non-responsiveness prediction through genetic profiling will help these high-risk patients to propose strategies to modify clopidogrel doses or use alternative antiplatelet drugs such as ticagrelor to prevent recurrent ischemic events and improve clinical outcomes.

Chan et al revealed that the carriage of *CYP2C19**3 and *17 mutant alleles was associated with HTPR in different directions.³³ *CYP2C19**3 reduced clopidogrel activation and was a positive predictor of HTPR. In contrast, *CYP2C19**17 enhanced clopidogrel activation and was inversely related to HTPR. However, in this study, no significant correlation was found between *CYP2C19**3 or *17 and the occurrence of HTPR. The difference may be related to their low gene distribution frequencies.

In this study, TEG was applied to test platelet function. Compared with the gold standard light transmittance aggregometry (LTA) method, TEG has the advantages of convenient operation and good reproducibility, and can provide comprehensive information about the coagulation cascade reaction. In addition, we used PCR-RFLP method to detect *CYP2C19* polymorphisms. Compared with the gold standard Sanger sequencing method, it has the advantages of high throughput and simple operation.

This study had several limitations. First, in this study, the bias of other genetic polymorphisms involved in the oxidative activation of clopidogrel, such as *CYP1A2*, *2B6*, *3A*, and *2C9*, was not excluded. Secondly, all participants in this study were patients over 18 years old, so the findings of this study might not be applicable to patients under 18 years old. Again, in a recently published article, TEG was reported to be not quite suitable for clopidogrel effect detection.³⁴ However, our platelet function was detected by TEG, but not confirmed by other methods. Finally, we did not collect follow-up data on MACE in the enrolled patients, so

we could not provide direct evidence of the impact of *CYP2C19* polymorphisms on clinical outcomes.

Conclusion

In this study, we investigated the association between *CYP2C19* polymorphisms and HTPR in clopidogrel-treated Chinese Han patients. Results indicated that *CYP2C19**2 A allele was a related factor of HTPR events in IS patients with T2DM, but not in patients without T2DM. To validate our findings, future studies with larger sample sizes, more genetic variants, more comprehensive subgroup design, better reliability confirmation of results, and appropriate follow-up are necessary. The current results may help predict the situation of HTPR in different patient populations, guide the rational use of drugs, and reduce the incidence of adverse vascular events.

Funding

This work was funded by grants from the National Natural Science Foundation of China (No: 81903872), and the Natural Science Foundation of Shandong Province (No: ZR2019MH077).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. *Stroke*. 2018;49(3):e46–e110. doi:10.1161/STR.000000000000158
2. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. *Stroke*. 2019;50(12):e344–e418. doi:10.1161/STR.000000000000211
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324(7329):71–86. doi:10.1136/bmj.324.7329.71
4. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with st-elevation myocardial infarction: a randomized clinical trial. *JAMA Cardiol*. 2018;3(5):391–399. doi:10.1001/jamacardio.2018.0612
5. Andreou I, Briasoulis A, Pappas C, Ikonomidis I, Alexopoulos D. Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis. *Cardiovasc Drugs Ther*. 2018;32(3):287–294. doi:10.1007/s10557-018-6795-9
6. Pan YS, Jing J, Chen WQ, et al. Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE. *Neurology*. 2017;88(20):1906–1911. doi:10.1212/WNL.0000000000003941

7. Ray S. Clopidogrel resistance: the way forward. *Indian Heart J.* 2014;66(5):530–534. doi:10.1016/j.ihj.2014.08.012
8. Yeo KK, Armstrong EJ, Lopez JE, et al. Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. *Catheter Cardiovasc Interv.* 2018;91(7):1308–1317. doi:10.1002/ccd.27453
9. Bomicke T, Valina CM, Stratz C, Amann M, Neumann FJ, Hochholzer W. On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. *Thromb Haemost.* 2017;117(8):1644–1650. doi:10.1160/TH17-02-0122
10. Chung JW, Kim SJ, Hwang J, et al. Comparison of clopidogrel and ticlopidine/ginkgo biloba in patients with clopidogrel resistance and carotid stenting. *Front Neurol.* 2019;10:44. doi:10.3389/fneur.2019.00044
11. Mangiacapra F, Peace A, Barbato E, et al. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. *Platelets.* 2014;25(5):348–356. doi:10.3109/09537104.2013.824562
12. De Servi S, Crimi G, Calabro P, et al. Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. *EuroIntervention.* 2016;12(3):312–318. doi:10.4244/EIJV12I3A51
13. Clavijo LC, Al-Asady N, Dhillon A, et al. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. *Cardiovasc Revasc Med.* 2018;19(5Pt A):516–520. doi:10.1016/j.carrev.2017.10.013
14. Angiolillo DJ, Jakubowski JA, Ferreira JL, et al. Impaired responsiveness to the platelet P2Y₁₂ receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. *J Am Coll Cardiol.* 2014;64(10):1005–1014. doi:10.1016/j.jacc.2014.06.1170
15. Zhang DY, Zhang XL, Liu D, et al. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. *Cardiovasc Diabetol.* 2016;15:50. doi:10.1186/s12933-016-0362-0
16. Samos M, Fedor M, Kovar F, et al. Type 2 diabetes and ADP receptor blocker therapy. *J Diabetes Res.* 2016;2016:6760710. doi:10.1155/2016/6760710
17. Lee J, Cheng N, Tai H, et al. CYP2C19 polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb ischaemia. *Eur J Vasc Endovasc Surg.* 2019;58(3):373–382. doi:10.1016/j.ejvs.2019.02.011
18. CPIC [website on the Internet]. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013; update September 2013; 2013. Available from: <https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/>. Accessed October 20, 2020.
19. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. *Clin Pharmacol Ther.* 2011;90(2):328–332. doi:10.1038/clpt.2011.132
20. Pan YS, Chen WQ, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Circulation.* 2017;135(1):21–33. doi:10.1161/CIRCULATIONAHA.116.024913
21. Wu Y, Zhou YL, Pan YS, et al. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. *Pharmacogenomics J.* 2018;18(6):713–720. doi:10.1038/s41397-018-0018-4
22. Liu GH, Yang SF, Chen SQ. The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention. *Medicine.* 2020;99(11):e19143. doi:10.1097/MD.00000000000019143
23. WHO-IDF [website on the Internet]. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation; 2006. Available from: <https://apps.who.int/iris/handle/10665/43588>. Accessed October 30, 2017.
24. Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. *J Am Coll Cardiol.* 2010;56(20):1630–1636. doi:10.1016/j.jacc.2010.07.004
25. Wang SM, Zhu AP, Li D, Wang Z, Zhang P, Zhang GL. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. *J Hum Genet.* 2009;54(6):372–375. doi:10.1038/jhg.2009.41
26. Yan XH, Zhang SN, Liang JP, et al. A PCR-lateral flow assay system based on gold magnetic nanoparticles for CYP2C19 genotyping and its clinical applications. *Artif Cells Nanomed Biotechnol.* 2019;47(1):636–643. doi:10.1080/21691401.2019.1575841
27. Hassani Idrissi H, Hmimch W, Khorb NE, Akoudad H, Habbal R, Nadifi S. A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with clopidogrel resistance among moroccan acute coronary syndromes patients. *BMC Res Notes.* 2018;11(1):46. doi:10.1186/s13104-018-3132-0
28. Sukasem C, Tunthong R, Chamnanphon M, et al. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. *Pharmgenomics Pers Med.* 2013;6:85–91. doi:10.2147/PGPM.S42332
29. Zhang ZW, Chen MX, Zhang L, Zhao Q. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. *BMC Pharmacol Toxicol.* 2020;21(1):1. doi:10.1186/s40360-019-0378-7
30. Semiz S, Dujic T, Ostanek B, et al. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. *Bosn J Basic Med Sci.* 2010;10(4):287–291. doi:10.17305/bjbm.2010.2662
31. Guo YM, Zhang L, Li HZ, Ma XM. Relationship between CYP2C19 gene polymorphism and anti-platelet effect of clopidogrel in elderly patients with coronary heart disease complicated with T2DM after PCI. *Clin Med.* 2019;30(8):25–27. doi:10.1038/s41397-018-0018-4
32. Chouchene S, Dabboubi R, Raddaoui H, et al. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype? *Eur J Clin Pharmacol.* 2018;74(12):1567–1574. doi:10.1007/s00228-018-2530-5
33. Chan MY, Tan K, Tan HC, et al. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. *Pharmacogenomics.* 2012;13(5):533–542. doi:10.2217/pgs.12.24
34. Shao T, Cheng Y, Jin J, et al. A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy. *J Clin Neurosci.* 2020;78:91–96. doi:10.1016/j.jocn.2020.06.004

Pharmacogenomics and Personalized Medicine

Dovepress

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed

on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>